首页|Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results

Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results

扫码查看
原文链接
  • 万方数据

dosimetryhypofractionationmagnetic resonance imagingprostate cancerradiation doseradiotherapy

Gao Linrui、Wei Ran、Qin Shirui、Tian Yuan、Xia Wenlong、Song Yongwen、Wang Shulian、Fang Hui、Tang Yu、Jing Hao、Liu Yueping、Tang Yuan、Qi Shunan、Chen Bo、Li Yexiong、Xing Nianzeng、Lu Ningning

展开 >

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

GCP Center/Clinical Research Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Department of Urology, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

dosimetry hypofractionation magnetic resonance imaging prostate cancer radiation dose radiotherapy

Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences, Longevity and Health Project

2021-JKCS-003

2024

10.1002/cdt3.114

慢性疾病与转化医学(英文)

慢性疾病与转化医学(英文)

CSTPCD
ISSN：2095-882X
年,卷(期)：2024.10(1)
  • 22